| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.090 | Biomarker | disease | BEFREE | MTAP staining demonstrated generally good concordance between the cytologic and surgical specimens and appears to be useful in the diagnosis of mesothelioma on effusion specimens. | 31821740 | 2020 | ||||
|
0.090 | Biomarker | disease | BEFREE | Combinations of staining using cyclin D1 >50% plus BAP1 or MTAP loss in epithelial mesotheliomas produced about a 10% increase in sensitivity. | 31685964 | 2020 | ||||
|
0.090 | Biomarker | disease | BEFREE | We performed MTAP immunohistochemistry on 20 benign mesothelial lesions and 99 malignant mesotheliomas from five mesothelioma centers in four countries, and each MTAP stain was independently interpreted by four pathologists. | 31231127 | 2020 | ||||
|
0.090 | Biomarker | disease | BEFREE | A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma. | 29053210 | 2018 | ||||
|
0.090 | Biomarker | disease | BEFREE | Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry. | 28213009 | 2017 | ||||
|
0.090 | Biomarker | disease | BEFREE | The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas. | 22394205 | 2012 | ||||
|
0.090 | GeneticVariation | disease | BEFREE | Nine of 26 (35%) peritoneal mesotheliomas had homozygous deletion of CDKN2A; MTAP was co-deleted in every case. | 20081810 | 2010 | ||||
|
0.090 | Biomarker | disease | BEFREE | The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of de novo AMP synthesis. | 15950811 | 2005 | ||||
|
0.090 | Biomarker | disease | BEFREE | Thus, the particularly high prevalence of MTAP codeletion in mesothelioma makes it an ideal candidate for trials of targeted therapy using inhibitors of de novo AMP synthesis (e.g., L-alanosine). | 12796375 | 2003 |